Hinova (688302. SH) is an international and clinical-stage pharmaceutical company focusing on developing new therapeutics for cancers and metabolic syndromes through PROTAC and deuteration technology. We are committed to the discovery and development of innovative drugs with global interests that meet significant clinical needs.
Hinova Pharma has 4 core R&D platforms, which are the PROTAC Platform, Deuteration Platform, Novel Target Discovery and Validation Platform, and Translational Medical Technology Platform. We have submitted more than 200 PCT and national patents, with more than 90 patents granted in China and in the globe, such as the US, EU, and Japan. We have 13 innovative projects in the R&D stage, and 2 National Major Projects of "Significant New Drugs Creation" awarded by the Ministry of Science and Technology of the People’s Republic of China. Hinova Pharma is led by a management team comprised of accomplished experts in both the biotechnology and pharmaceutical industries. Our core team members are mostly from the world's Top 500 pharmaceutical companies, with 2 national-level and several provincial-level experts.
Among our pipeline and programs:
✔ Deutenzalutamide (HC-1119), for the treatment of castration-resistant prostate cancer (mCRPC) has entered the
global multicenter Phase III clinical trials and the Phase III clinical trial in Chinese Patients with mCRPC have met
the primary endpoint, the NDA application of HC-1119 was accepted by NMPA in March 2023;
✔ HP501, for the treatment of hyperuricemia and gout, has been studied in several phase I/II trials as a single agent;
✔ HP558, which is potentially effective for esophageal squamous cell carcinoma treatment, has been approved by
NMPA for the Phase II clinical trial;
✔ HP518, an orally bioavailable chimeric degrader targeting AR, is in Phase I clinical trials in Australia, and its IND
application has been approved by the FDA;